PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Targeted Therapies Holds Huge Potential for Prostate Cancer Therapeutics Market in China Finds Frost & Sullivan - New analysis from Frost & Sullivan, Opportunities Assessment for Breast Cancer Therapeutics in China, finds that the total number of breast cancer patients in the country was 387,000 in 2009
Targeted Therapies Holds Huge Potential for Prostate Cancer Therapeutics Market in China Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Singapore, Singapore, 2009/10/19 - New analysis from Frost & Sullivan, Opportunities Assessment for Breast Cancer Therapeutics in China, finds that the total number of breast cancer patients in the country was 387,000 in 2009.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Growth in innovative targeted therapies set to drive breast cancer therapeutics market in China, notes Frost & Sullivan.

Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in China. Currently, a larger number of breast cancer patients are pre-treated with taxanes as adjuvant chemotherapy is widely used and breast cancer is diagnosed earlier. In the future, the use of molecular targeted therapies as effective forms of cancer therapy will become more prevalent. However, drug manufacturers and the government need to work hand-in-hand in making these advanced therapies more accessible to the market.

New analysis from Frost & Sullivan (pharma.frost.com), Opportunities Assessment for Breast Cancer Therapeutics in China, finds that the total number of breast cancer patients in the country was 387,000 in 2009, and estimates this to increase by more than 20 percent within 2016. The study provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in China.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Jasminder Kaur, Corporate Communications, at jkaur[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

For now, molecular targeted therapies form a majority of the drugs in clinical development for breast cancer, followed by cytotoxic therapies and endocrine therapies. Biopharmaceutical companies are placing more emphasis on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well.

"Targeted therapeutics are the emerging trend in cancer therapies that rely on the biological differences between malignant and healthy cells to target the faulty genes or proteins that play a crucial role in breast cancer development," says Frost & Sullivan Research Analyst Carole Gaffud. "Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies are rapidly becoming the standard of oncology care."

In China, there is a growing acceptance of targeted therapies for breast cancer. Breast cancer surgeons and medical oncologists regard targeted therapies as relatively safe treatments that are to be increasingly used in the future in China. Three targeted therapies in late-phase development include Certican/Afinitor (Novartis), Armala (GlaxoSmithKline), and Omnitarg (Roche).

"Although medical oncologists in China have shown high interest in the potential of new biological treatments, the high cost of biologicals is a major challenge and some specialists believe that their response does not justify the expense," notes Gaffud.

Due to the higher cost compared to cytotoxic and endocrine therapies, the use of targeted therapies in China is and would continue to be largely dependent on their price and availability on the National Reimbursement List. Those regimens believed to be the ‘optimal standard of care’, such as monoclonal antibodies and aromatase inhibitors, are not reimbursed in either early or advanced stage of the disease. And as most patients do not have the financial capability to afford these treatments; they are prescribed reimbursable products, which may have lower efficacy or present higher side effects.

"Overall, to thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life," concludes Gaffud. "At the same time, they could consider providing access to more drugs in pharmacies and hospitals at a lower cost."

Opportunities Assessment for Breast Cancer Therapeutics in China, is part of the Pharmaceutical & Biotechnology Growth Partnership Service program, which also includes research in the therapeutics market for Rheumatoid Arthritis, Hepatitis B, and Type 2 Diabetes, as well as the outlook for the pharmaceutical and biotechnology markets in various Asia Pacific countries. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

Opportunities Assessment for Breast Cancer Therapeutics in China

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Targeted Therapies Holds Huge Potential for Prostate Cancer Therapeutics Market in China Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Jasminder Kaur 
+65.6890.0937 jkaur[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)